As Precision Medicine and Genomics move to the center of global drug development, the complexity of managing distributed R&D increases exponentially. India offers significant advantages in NGS throughput and bioinformatics, yet global innovators face systemic risks in data fidelity, clinical relevance, and regulatory bridging.
Aventiq Bio serves as your Independent Technical Proxy in India. We provide high-level governance for NGS platforms, biomarkers, and Companion Diagnostics (CDx), ensuring that genomics-driven programs are built on audit-ready data and defensible partner intelligence.
We perform no sequencing or bioinformatics. Our neutrality ensures unbiased partner vetting and objective data audits.
Specialized governance for patient stratification, oncology biomarkers, and CDx-linked assets.
Advisory frameworks designed to bridge Indian NGS operations and FDA/EMA/CLIA standards.
On-ground, technical due diligence of NGS and Bioinformatics providers.
Maturity scoring based on quality systems, platform stability, and historical compliance.
Managing the critical interface between diagnostic developers and therapeutic sponsors.
Oversight of analytical validation strategies to prevent late-stage approval delays.
Independent review of variant calling pipelines and bioinformatics QC controls.
Ensuring "Audit-Ready" traceability from raw FASTQ files to clinical reports.
Advisory on patient stratification strategies and biomarker validation protocols.
Structuring data packages to meet the evolving requirements of global regulatory bodies.
FDA/EMA CDx Alignment
CLIA/CAP Quality Benchmarks
ALCOA+ Data Standards
Ironclad IP Firewalls